Biogen swoops to appoint Ex-Roche Vice President
pharmafile | March 16, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Biogen
Biogen have appointed Anirvan Ghosh to the position of Senior Vice President of research and Early Development. Ghosh is slated to begin his role in April, leaving his current position of Chief Scientific Officer at E-Scape Bio, a biotech company focusing on therapies for Alzheimer’s disease.
Prior to this role, he held the position of Vice President, Global Head of Neuroscience Discovery and Biomarkers at Roche. In this role, he focused on research and drug discovery for neurodegenerative diseases and it is this expertise that has attracted Biogen to making this appointment.
“We are excited to have Anirvan Ghosh join us at Biogen,” said Dr Ehlers, Executive Vice President, Head of Research and Development. “After an extensive global search, we have found an inspired leader to guide an exceptional Research and Early Development team. Anirvan is an accomplished neuroscientist and industry R&D leader who has delivered multiple novel drug candidates to the clinic.”
Commenting on his own reasons for joining the company, Dr Ghosh said, “Biogen has been a pioneer in bringing breakthrough medicines to patients with multiple sclerosis and spinal muscular atrophy, as well as finding new approaches for Alzheimer’s disease, Parkinson’s disease, and ALS – conditions that represent some of the hardest challenges in medicine. I am excited and honoured to lead Research and Early Development, and I look forward to accelerating our efforts to translate the highest quality science and our best ideas into a new generation of medicines at Biogen.”
Related Content
Biogen and Stoke report positive results for Dravet syndrome drug
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a …
FDA accepts Eisai’s Leqembi sBLA for early AD treatment
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted …
